The National Cancer Institute seeks licensing and/or co-development research collaborations for further development of antibodies that selectively target IL-7Rα, a major driver of T-cell derived ALL (T-ALL) and an important therapeutic target for a range of diseases.
Researchers at the National Institute on Aging working on cancer immunotherapy and detection report the use of SPANX-B polypeptides in the treatment and identification of cancer. Specific human malignancies targeted for the treatments disclosed include melanoma and lung, colon, renal, ovarian and breast carcinomas. The NIA seeks parties interested in licensing or collaborative research to further develop, evaluate, or commercialize SPANX-B polypeptides in the treatment and identification of cancer.
Researchers at the NCI have developed immunologically active peptides of NGEP that activate cytotoxic lymphocytes to effectively kill prostate cancer cells. These peptides can be applied to multiple immunotherapy strategies to treat and prevent prostate cancer.
The National Cancer Institute’s Pediatric Oncology Branch seeks partners interested in licensing or collaborative research to co-develop new immunotherapeutic agents based on chimeric antigen receptor (CARs) for the treatment of pediatric solid tumors.
The National Cancer Institute (NCI) Vaccine Branch, seeks research co-development or licenses for a novel method of improving HIV vaccine efficacy by activating Ras signaling. Upregulating the Ras pathway can improve an HIV patient’s immune response to anti-retroviral vaccines.
The National Cancer Institute’s Surgery Branch seeks partners interested in collaborative research to co-develop adoptive transfer of tumor infiltrating leukocytes (TIL) for cancers other than melanoma.
The thymus is the only organ capable of producing conventional, mature T cells; a crucial part of the adaptive immune system. However, its efficiency and function are progressively reduced as we age, leading to a compromised immune system in the elderly. Moreover, production of T cells with specific receptors is an important concern for cancer immunotherapy. Current in vitro methods produce immature T cells that are not useful for therapy. Researchers at the National Cancer Institute (NCI) have generated an autologous thymic organoid from human pluripotent stem cells to address this problem. The organoid can be used to develop clinical applications such as production of autologous T and natural killer T (NKT) cells and reconstitution of the adaptive immune system. NCI is seeking licensees for the thymic organoid and the method of its generation to be used in a variety of clinical applications.
To improve the therapeutic effectiveness of PE-based immunotoxins through multiple rounds of drug administration, NIH inventors have sought to identify and remove the human B cell epitopes within PE. Previous work demonstrated that the removal of the murine B cell and T cell epitopes from PE reduced the immunogenicity of PE and resulted in immunotoxins with improved therapeutic activity. The National Cancer Institute's Laboratory of Molecular Biology seeks interested parties to co-develop and commercialize immunotoxins using toxin domains lacking human B cell epitopes.
Researchers at the National Cancer Institute (NCI) developed a potential nucleic acid-based therapy using an inducible activation nucleic acid hybrid switch for conditional generation of oligonucleotides. The NCI is looking for innovative companies interested in co-developing and/or licensing this technology.
Researchers at the National Cancer Institute (NCI) have developed a method by which memory T cells can be generated from other T cell populations using overexpression of the transcription factor c-Myb. Importantly, these reprogrammed memory T cells show increased proliferative and survival capacity. This strategy could also potentially generate anti-tumor T cells with improved viability and therapeutic efficacy for adoptive ACT. Researchers at the NCI seek licensing and/or co-development research collaborations for this invention.
Researchers at the National Cancer Institute (NCI) and the National Heart Lung and Blood Institute (NHLBI) have discovered a method of improving adoptive T cell therapy by preconditioning CD8+ T cells with a lactate dehydrogenase (LDH) inhibitor. NCI seeks research co-development partners and/or licensees for clinical evaluation of the invention.
Researchers at the National Eye Institute (NEI) have developed a novel therapeutic strategy of using recombinant IL-24 protein to treat inflammatory diseases that involve the proinflammatory T-helper 17 cell (Th17) response, such as uveitis, multiple sclerosis, rheumatoid arthritis, and Crohn’s disease. Researchers at the NEI seek licensing and/or co-development research collaborations for co-developing this technology as strategic partners or licensing it for commercialization.
The National Institute on Aging, Laboratory of Clinical Investigation, is seeking parties interested in collaborative research to co-develop ketamine metabolites for the treatment of different forms of depression and for alleviating pain.
Researchers at the National Eye Institute (NEI) have generated Induced Pluripotent Stem Cells (iPS) from two Late-Onset Reginal (L-ORD) patients with a dominant mutation in CTRP5 protein and two of their unaffected siblings. All iPS cells were differentiated into authenticated Retinal Pigment Epithelium (RPE) cells. The NEI seeks licensing and/or co-development research collaborations for Metformin as an FDA-approved drug to treat Age-related Retinal Degeneration.
The National Eye Institute (NEI) and National Institute of Arthritis and Muscoskeletal and Skin Diseases (NIAMS) seeks licensing and/or co-development of a method of producing human retinal pigment epithelial (RPE) cells from human induced pluripotent stem cells (iPSCs).
The Protein Expression Laboratory at the National Cancer Institute in Frederick, MD is seeking statements of capability or interest from parties interested in collaborative research to further develop a platform technology for the targeted intra-cellular delivery of proteins using virus-like particles (VLPs).